Succession Planning for Emerging Biopharma Clinical Organizations

Succession planning sounds like a large-company concern. For an emerging biopharma sponsor, it is arguably more urgent, because the concentration risk is higher. When one person holds the operational history of a program, their departure is not an inconvenience. It is a material risk to the asset.

The concentration is easy to miss because it does not look like a single point of failure from the inside. The VP of Clinical Development knows why the Phase 1 dose escalation was modified, what the FDA said in the pre-IND meeting, which CRO functional lead is reliable and which is not, and why the protocol includes an unusual assessment that nobody has questioned in two years. None of that is written down anywhere. All of it is load-bearing.

Three practical steps reduce the exposure without requiring a formal talent management function.

Document decision history, not just decisions. Regulatory filings capture what was decided. They rarely capture why alternatives were rejected. A short program decision log, maintained as decisions are made rather than reconstructed later, is one of the highest-return documentation practices available to a small sponsor.

Create deliberate exposure. The clinical trial manager who has never attended a regulatory interaction, never sat in a governance meeting with the CRO's executive sponsor, and never seen the program budget is not a successor candidate regardless of their capability. Exposure is cheap and it compounds.

Identify the second name for every critical role. Not a formal succession plan, just an honest answer to a simple question: if this person left in six weeks, who would we ask to cover this, and what would they need to know? The gaps that question surfaces are usually specific and addressable.

Small sponsors sometimes avoid this conversation because it feels like planning for disloyalty. It is not. People leave for reasons that have nothing to do with commitment, including acquisitions, relocations, and health. A program that depends on a single person's memory is fragile in a way that has nothing to do with that person's intentions.